Distribution of natural resistance to NS3 protease inhibitors in hepatitis C genotype 1a separated into clades 1 and 2 and in genotype 1b of HIV-infected patients

S. Bagaglio, C. Uberti-Foppa, E. Messina, M. Merli, H. Hasson, A. Andolina, A. Galli, A. Lazzarin, G. Morsica

Research output: Contribution to journalArticle

Abstract

Naturally occurring resistance-associated variants (RAVs) within the protease domain of hepatitis C virus (HCV) genotype (G) 1a separated into clades 1 and 2, and G1b were investigated in 59 HIV/HCV coinfected patients. RAVs were detected in 10/23 G1a/clade 1 and 1/19 G1b (p 0.0059). A similar frequency of RAVs was found when comparing G1a/clade 2 and G1b (p 0.1672). A cross-resistance to the macrocyclic compounds simeprevir and paritaprevir was detected in two G1a/clade 2 and 1 G1b sequences and none of G1a/clade 1 sequences. The simultaneous characterization of subtype and natural RAVs by population analysis of the NS3 domain by may add important information for anti-HCV treatment strategies including protease inhibitors.

Original languageEnglish
JournalClinical Microbiology and Infection
DOIs
Publication statusAccepted/In press - Feb 12 2015

    Fingerprint

Keywords

  • Clades 1 and 2
  • Genotype 1a
  • HCV-PI
  • HIV
  • Natural RAV
  • Q80K polymorphism

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this